Medtronic/Kyphon merger gets early US OK:
This article was originally published in Clinica
Medtronic's proposed $3.9bn acquisition of balloon kyphoplasty specialist Kyphon has received the go-ahead from US regulators, who agreed to an early termination of the waiting period required under the US antitrust act. The transaction still requires regulatory approval from several other jurisdictions, as well as approval from Kyphon's shareholders, who will vote in a special meeting set for October 16.
You may also be interested in...
The Swiss major focused almost exclusively on the benefits of the combination of Tecentriq and its TIGIT inhibitor tiragolumab at ASCO but also celebrated the approval of a Tecentriq/Avastin combo for hepatocellular carcinoma.
Mylan first announced plans to develop a biosimilar of the Botox cosmetic and therapeutic brands back in 2018 through an alliance with Revance Therapeutics. More than two years later, a verdict has been reached by the company.
Separate concerns raised by the EMA over bioequivalence studies have led Mylan and Accord to withdraw generic applications, including the former’s generic version of Gilenya for the treatment of multiple sclerosis.